Biopharma financing in the fourth quarter ended 2018 on a low note, with companies raising an aggregate $10.9bn – a 25% decrease from Q3’s $14.6bn, and the lowest-valued quarter in terms of dollar value in 2018 (see Exhibit 1).
Biopharma Quarterly Dealmaking Statistics, Q4 2018
A look at financing, M&A and alliance activity October-December 2018
At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.
More from Deal-Making
More from In Vivo
• By
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
• By
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.